Shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) fell 7.3% during trading on Tuesday . The stock traded as low as $2.46 and last traded at $2.54. 547,963 shares were traded during mid-day trading, an increase of 1% from the average session volume of 540,728 shares. The stock had previously closed at $2.74.
Separately, Oppenheimer reissued a “buy” rating and issued a $5.00 target price on shares of CASI Pharmaceuticals in a report on Tuesday, November 10th.
The firm’s fifty day moving average price is $3.19 and its 200 day moving average price is $2.32. The stock has a market cap of $314.82 million, a PE ratio of -6.09 and a beta of 0.41.
CASI Pharmaceuticals Company Profile (NASDAQ:CASI)
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.
Recommended Story: Trade War
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.